文献速递真实世界研究与卫生经济流行病学与生物统计

美国移民中采用转录特征筛查潜伏结核感染的成本效益

Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants.
PubMed 文献 · PLoS Med · 2025-05-08

该研究使用离散事件仿真模型,比较四种入境后结核感染筛查策略:不筛查、仅IGRA、IGRA-HrTS、仅HrTS。假设HrTS满足WHO目标产品概况最优标准,在终生时间范围内评估2019年入境美国移民的健康影响与成本效益。结果显示,在每获得一个质量调整生命年支付意愿阈值为15万美元时,仅IGRA策略在医疗部门和社会视角下均为最优策略,增量成本效益比分别为每获得一个QALY 104,138美元和143,103美元;在支付意愿为10万美元/QALY时,IGRA-HrTS策略似乎最优。

要点

  • 在15万美元/QALY支付意愿阈值下,仅IGRA策略在医疗部门和社会视角下均为最优。
  • 在10万美元/QALY支付意愿阈值下,IGRA-HrTS策略似乎最优。
  • 按原籍国结核发病率分层,仅IGRA策略对发病率≥100/10万的国家最优,不筛查策略对发病率<10/10万的国家最优。

核心结论

  • 满足WHO目标产品概况最优标准的HrTS检测对美国部分移民的入境后筛查可能具有成本效益,但该结果对多种因素敏感。

研究设计与样本

  • 离散事件仿真模型,比较四种策略:不筛查、仅IGRA、IGRA-HrTS、仅HrTS。
  • 评估对象为2019年入境美国的移民,评估时间范围为终生,假设HrTS满足WHO目标产品概况最优标准。
  • 进行了敏感性分析以评估结果的稳健性。

主要发现

  • 在每获得一个QALY支付意愿阈值为15万美元时,仅IGRA策略在医疗部门视角和社会视角下均为最优策略,增量成本效益比分别为每获得一个QALY 104,138美元和143,103美元。
  • 在每获得一个QALY支付意愿阈值为10万美元时,IGRA-HrTS策略似乎最优。
  • 按原籍国结核发病率分层,仅IGRA策略对原籍国发病率≥100/10万的国家最优,不筛查策略对原籍国发病率<10/10万的国家最优。
  • IGRA-HrTS策略在原籍国发病率为10-100/10万时可能具有成本效益,但该结果存在大量不确定性。
  • 结果对美国入境后结核进展风险的时间趋势敏感。

关键数值与推荐

  • 仅IGRA策略:筛查所有个体使用IGRA,对IGRA阳性者提供结核预防性治疗。
  • IGRA-HrTS策略:筛查所有个体使用IGRA,对IGRA阳性者进行HrTS检测,对两项检测均阳性者提供潜伏结核感染治疗。
  • 仅HrTS策略:筛查所有个体使用HrTS,对HrTS阳性者提供潜伏结核感染治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • IGRA-HrTS策略在原籍国发病率为10-100/10万时可能具有成本效益,但该结果存在大量不确定性。
  • 结果对美国入境后结核进展风险的时间趋势敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Host-response-based transcriptional signatures (HrTS) have been developed to identify "incipient tuberculosis (TB)". No study has reported the cost-effectiveness of HrTS for post-arrival migrant screening programs in low-incidence countries. The aim of this study was to assess the potential health impact and cost-effectiveness of HrTS for post-arrival TB infection screening among new migrants in the United States. METHODS AND FINDINGS: We used a discrete-event simulation model to compare four strategies: (1) no screening for TB infection or incipient TB; (2) 'IGRA-only', screen all with interferon-gamma release assay (IGRA), provide TB preventive treatment for IGRA-positives; (3) 'IGRA-HrTS', screen all with IGRA followed by HrTS for IGRA-positives, provide incipient TB treatment for individuals testing positive with both tests; and (4) 'HrTS-only', screen all with HrTS, provide incipient TB treatment for HrTS-positives. We assessed outcomes over the lifetime of migrants entering the United Stataes (U.S.) in 2019, assuming HrTS met WHO Target Product Profile (TPP) optimal criteria. We conducted sensitivity analyses to evaluate the robustness of results. Our findings show that at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY) gained, the IGRA-only strategy was the optimal strategy under both healthcare sector and societal perspectives, with an incremental cost-effectiveness ratio (ICER) of $104,138 and $143,103 per QALY gained, respectively. At a willingness-to-pay of $100,000 per QALY gained the IGRA-HrTS strategy appeared optimal. When the cohort was stratified by TB incidence in the country-of-origin, the IGRA-only strategy was optimal for country-of-origin incidence [Formula: see text]100 per 100,000, and the no-screening strategy was optimal for country-of-origin incidence <10 per 100,000. The IGRA-HrTS strategy was potentially cost-effective with country-of-origin incidence of 10-100 per 100,000, though this result had substantial uncertainty. Results were sensitive to time trends in TB progression risk after U.S. entry. CONCLUSIONS: An HrTS test meeting WHO TPP optimal criteria would be potentially cost-effective for post-arrival screening among a subset of U.S. migrants, but this result was sensitive to multiple factors.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Hsieh YL, Horsburgh CR, Cohen T, et al. Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants. PLoS Med. 2025. PMID: 40338978. doi:10.1371/journal.pmed.1004603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。